Close
Close

CD36

CD36


CD36 CD36 (Cluster of Differentiation 36) is a scavenger receptor expressed in many cell types, which is associated with various diseases, including infection, Alzheimer's disease, cancer, and metabolic diseases. As a transmembrane glycoprotein, CD36 contains multiple post-translational modification sites and can bind to a variety of ligands, such as thrombospondin-1 (TSP-1), apoptotic cells and fatty acids (FA). CD36 can promote tumor metastasis and treatment resistance by enhancing lipid uptake and FA oxidation. In addition, CD36 inhibits angiogenesis by binding to TSP-1, thereby inducing apoptosis or blocking the vascular endothelial growth factor receptor 2 (VEGFR2) pathway in tumor microvascular endothelial cells. At the same time, in tumor-associated immune cells, CD36-driven reprogramming and functions of lipid metabolism lead to tumor immune tolerance and cancer development. Therefore, CD36 is now considered to have great potential in cancer diagnosis and targeted therapy.

In view of the important role of CD36 in tumorigenesis, development, and metastasis, many preclinical studies and clinical trials on CD36 have been and are under way. Inhibition of CD36-mediated FA uptake is one of strategies for metastatic tumor treatment. Studies of targeting TSP-1 binding to CD36 have also made progress. Three modified TSR peptides (ABT-526, ABT-510, and ABT-898) have been found to be effective in animal experiments, and ABT-510 was even approved to enter Phase 2 clinical trial. In addition, TAX2, derived from CD47, induces the transformation of the binding target of TSP-1 from CD47 to CD36, resulting in anti-angiogenesis in tumors. Further research on CD36 will help explore new strategies for drug discovery and cancer treatment.

Creative Biolabs has developed a series of CD36 membrane protein products in different formats, including detergent, liposome, VLP, nanodisc, and SMALPs/Polymers to fit your requirements. They show very good performance in functional studies, antibody development, drug discovery, structure determination (NMR spectroscopy, crystallization, Cryo-EM), etc.


References

  1. Wang J, Li Y. CD36 tango in cancer: signaling pathways and functions. Theranostics. 2019 Jul 9;9(17):4893-4908.
  2. Park YM. CD36, a scavenger receptor implicated in atherosclerosis. Exp Mol Med. 2014 Jun 6;46(6):e99.
  3. Wang H, et. al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat Immunol. 2020 Mar;21(3):298-308.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Loading...
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2024 Creative Biolabs. | Contact Us